Peptide Initiative

Peptides · Peptide comparison

Pemvidutide vs Retatrutide

Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.

The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangePemvidutide1.8–1.8 mgRetatrutide4–8 mg
FrequencyPemvidutideOnce dailyRetatrutideOnce weekly
AdministrationPemvidutideSubcutaneous injectionRetatrutideSubcutaneous injection
Cycle lengthPemvidutideOngoing/indefiniteRetatrutide12+ weeks
Onset speedPemvidutideModerate (1-2 weeks)RetatrutideModerate (1-2 weeks)
Evidence levelPemvidutideModerate human trials (Phase 1-2)RetatrutideModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

Weight Loss

Pemvidutide92%
RetatrutideNo recorded rating

Liver Health

Pemvidutide95%
RetatrutideNo recorded rating

Metabolic Health

Pemvidutide88%
Retatrutide95%

Weight Loss Power

PemvidutideNo recorded rating
Retatrutide98%

Appetite Control

PemvidutideNo recorded rating
Retatrutide94%

Technical data

Compound specifications

Pemvidutide

Molecular formula
C182H275N39O54
Molecular weight
3873.35 Da
Half-life
Approximately 110 hours (4.6 days)
Bioavailability
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
CAS number
2538014-94-5

Retatrutide

Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2

Protocols

Dosing compared

Pemvidutide

Subcutaneous

  • 48 weeks1.2 mgOnce weekly · 48 weeksLowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].
  • 48 weeks1.8 mgOnce weekly · 48 weeksMid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].
  • 48 weeks2.4 mgOnce weekly · 48 weeksHighest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].

Retatrutide

Subcutaneous

  • Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
  • Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
  • Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).

Applications

Best suited for

Pemvidutide

Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].

Retatrutide

Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.

Safety profile

Side effects

Pemvidutide

Common

  • Nausea
  • Diarrhea
  • Headache

Uncommon

  • Vomiting
  • Decreased Appetite

Serious

  • Acute Pancreatitis
  • Severe Gastrointestinal Disturbance

Retatrutide

Common

  • Nausea
  • Diarrhea
  • Constipation
  • Decreased appetite

Uncommon

  • Increased heart rate
  • Injection site reactions

Serious

  • Pancreatitis
  • Gallbladder problems

Research status

Safety & evidence

Pemvidutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) [3][5] completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.

Contraindications

  • Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
  • Known hypersensitivity to pemvidutide or formulation components
  • History of acute pancreatitis
  • Severe hepatic decompensation (Child-Pugh C cirrhosis)

Retatrutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy or planning to become pregnant
  • History of severe pancreatitis
  • Known allergy to GLP-1 receptor agonists

Decision guide

Which is right for you?

Pemvidutide

Choose Pemvidutide if…

  • Adults seeking substantial weight loss without complex dose titration
  • Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
  • Patients with metabolic syndrome who need comprehensive risk factor improvement
  • Those interested in investigational dual agonist therapies with strong early data

Retatrutide

Choose Retatrutide if…

  • Significant weight loss
  • Type 2 diabetes management
  • Metabolic health improvement
  • Body composition optimization